Compare Tango Therapeutics Inc. (TNGX) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vertiv Holdings Co — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Vertiv Holdings Co trades at $217.31 (market cap $91.35B). The key difference: Vertiv Holdings Co is far larger — about 24.4× Tango Therapeutics Inc.'s market cap, and Vertiv Holdings Co pays a 0.11% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vertiv Holdings Co for 40 Days on average.
| TNGX | VRT | |
|---|---|---|
Market Cap | $3.75B | $91.35B |
Volume | 9,619,106 | 4,805,860 |
Sector | Health | Industrials |
52-Week High | $32.90 | $376.23 |
52-Week Low | $7.50 | $149.83 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $2.77B | $91.58B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Vertiv (VRT) trades at $237.29, down 0.86% on the day, amid a bearish technical signal. The stock exhibits strong fundamentals with revenue growth from $10.23B in 2025 to $11.5B projected for 2026 and a robust net income margin of 15.09%. Recent earnings have consistently beaten estimates, and analyst sentiment remains overwhelmingly positive with a 90.48% buy rating and a consensus price target of $366.12. However, technical indicators show selling pressure, with the price near support at $237.
The outlook for VRT is favorable due to its strategic position in the AI data center infrastructure market, driving revenue and margin expansion. Key risks include execution of growth initiatives, competitive pressures, and market volatility. The significant upside to the analyst target presents a potential opportunity, but investors should weigh the strong fundamentals against the current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
